Journal
ONCOGENE
Volume 30, Issue 13, Pages 1497-1505Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.548
Keywords
neuroendocrine tumors; somatostatin; chemoembolization
Funding
- NCI NIH HHS [K12 CA133250] Funding Source: Medline
Ask authors/readers for more resources
Neuroendocrine tumors (NETs) are a complex group of malignancies with variable prognosis and response to treatment. For pancreatic neuroendocrine and carcinoid tumors, traditional cytotoxic chemotherapies have demonstrated minimal activity. Current approaches for treatment of metastatic disease use a combination of loco-regional and targeted biological therapies. Clinical trials remain critical for evaluation of new and promising therapeutic options for patients with NETs. Oncogene (2011) 30, 1497-1505; doi: 10.1038/onc.2010.548; published online 6 December 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available